{
    "clinical_study": {
        "@rank": "4976", 
        "arm_group": [
            {
                "arm_group_label": "Brexpiprazole", 
                "arm_group_type": "Experimental", 
                "description": "Treatment (6 weeks) Up to 4 mg/day, once daily dose, tablets, orally"
            }, 
            {
                "arm_group_label": "Aripiprazole", 
                "arm_group_type": "Experimental", 
                "description": "Aripiprazole - Up to 20 mg/day, once daily dose, tablets, orally"
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this study is to explore changes in efficacy, cognitive functioning, and\n      safety of flexibly-dosed brexpiprazole monotherapy in subjects with acute schizophrenia"
        }, 
        "brief_title": "Brexpiprazole (OPC-34712) Trial in the Treatment of Adults With Acute Schizophrenia", 
        "completion_date": {
            "#text": "December 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Schizophrenia", 
        "condition_browse": {
            "mesh_term": "Schizophrenia"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  18 to 65 years of age, inclusive, at the time of informed consent with a diagnosis of\n             schizophrenia as defined by the Diagnostic and Statistical Manual of Mental\n             Disorders, Fourth Edition, Text Revision (DSM-IV-TR) and confirmed by the Mini\n             International Neuropsychiatric Interview (M.I.N.I) for Schizophrenia and Phychotic\n             Disorders Studies\n\n          -  Would benefit from hospitalization or continued hospitalization for treatment of a\n             current acute relapse of schizophrenia at trial entry\n\n          -  Are experiencing an acute exacerbation of psychotic symptoms and marked deterioration\n             of usual function as demonstrated by all of the following:\n\n          -  Positive and Negative Syndrome Scale (PANSS) Total Score of \u2265 80\n\n          -  Score of \u2265 4 on two or more of the following PANSS items at screening: hallucinatory\n             behavior, unusual thought content, conceptual disorganization, or suspiciousness\n\n          -  Clinical Global Impression - Severity of Illness Scale (CGI-S) score \u2265 4 (moderately\n             ill)\n\n        Exclusion Criteria:\n\n          -  Are presenting with a first episode of schizophrenia based on the clinical judgment\n             of the investigator\n\n          -  Have been hospitalized > 21 days for the current acute episode at the time of the\n             baseline visit\n\n          -  Have a current DSM-IV-TR Axis I diagnosis other than schizophrenia, including, but\n             not limited to, schizoaffective disorder, major depressive disorder (MDD), bipolar\n             disorder, post-traumatic stress disorder, anxiety disorders, delirium, dementia,\n             amnestic, or other cognitive disorders; also borderline, paranoid, histrionic,\n             schizotypal, schizoid, antisocial personality disorders or mental retardation.\n\n          -  Improvement of \u2265 20% in total PANSS score between the screening and baseline\n             assessments."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "65 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "81", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "February 2, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02054702", 
            "org_study_id": "331-13-008"
        }, 
        "intervention": [
            {
                "arm_group_label": "Brexpiprazole", 
                "description": "Treatment (6 weeks) Up to 4 mg/day, once daily dose, tablets, orally", 
                "intervention_name": "Brexpiprazole", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Aripiprazole", 
                "description": "Up to 20 mg/day, once daily dose, tablets, orally", 
                "intervention_name": "Aripiprazole", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Aripiprazole"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "Schizophrenia", 
            "Mental Disorders", 
            "Psychotic Disorders", 
            "Antipsychotic", 
            "Cognitive testing"
        ], 
        "lastchanged_date": "February 2, 2014", 
        "number_of_arms": "2", 
        "official_title": "Protocol 331-13-008: An Exploratory, Multicenter, Open-label, Flexible-dose Brexpiprazole (OPC-34712) Trial in Adults With Acute Schizophrenia", 
        "overall_contact": {
            "last_name": "Brexpiprazole.Program@quintiles.com"
        }, 
        "overall_official": {
            "affiliation": "Department of Clinical Research and Development, Otsuka Pharmaceutical Co., Ltd Japan (OPCJ)", 
            "last_name": "Yuko Hamatake", 
            "role": "Study Director"
        }, 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": [
                "United States: Food and Drug Administration", 
                "United States: Institutional Review Board"
            ], 
            "has_dmc": "No"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "December 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "The change from baseline to Week 6 in PANSS Total Score", 
            "safety_issue": "No", 
            "time_frame": "Week 6"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02054702"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Cognitive test battery composite score change from baseline to Week 6 change from baseline to Week 6 in cognitive test battery composite score change from baseline to Week 6 in cognitive test battery CGI-S score change from baseline to Week 6", 
                "safety_issue": "No", 
                "time_frame": "Week 6"
            }, 
            {
                "measure": "CGI-I score at Week 6", 
                "safety_issue": "No", 
                "time_frame": "Week 6"
            }, 
            {
                "measure": "Response rate", 
                "safety_issue": "No", 
                "time_frame": "Week 6"
            }, 
            {
                "measure": "SLOF Total Score change from baseline to Week 6", 
                "safety_issue": "No", 
                "time_frame": "Week 6"
            }, 
            {
                "measure": "BIS-11 total score change from baseline to Week 6", 
                "safety_issue": "No", 
                "time_frame": "Week 6"
            }
        ], 
        "source": "Otsuka Pharmaceutical Development & Commercialization, Inc.", 
        "sponsors": {
            "collaborator": {
                "agency": "Otsuka Pharmaceutical Co., Ltd.", 
                "agency_class": "Industry"
            }, 
            "lead_sponsor": {
                "agency": "Otsuka Pharmaceutical Development & Commercialization, Inc.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "February 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "February 2014"
    }
}